Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
PaxMedica, Inc. (PXMD)
NASDAQ:PXMD
PaxMedica, Inc. (PXMD) Stock Price & Analysis
13 Followers
PXMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.26 - $10.48
Previous Close$1.36
Volume25.79K
Average Volume (3M)1.08M
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$3.99M
Total Debt (Recent Filing)$1.54M
Price to Earnings (P/E)-0.8
Beta1.13
Next Earnings
May 15, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding14,619,477
10 Day Avg. Volume148,327
30 Day Avg. Volume1,083,101
Standard Deviation0.19
R-Squared0.33
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)180.06
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PaxMedica, Inc. News
Press ReleasesPaxMedica Holds Meeting of Scientific Advisory Board
Press ReleasesPaxMedica Releases 2022 Shareholder Letter
Market NewsPaxMedica Zooms on Bagging $3.2M Funding Win
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PXMD FAQ
What was PaxMedica, Inc.’s price range in the past 12 months?
PaxMedica, Inc. lowest stock price was $1.26 and its highest was $10.48 in the past 12 months.
What is PaxMedica, Inc.’s market cap?
Currently, no data Available
When is PaxMedica, Inc.’s upcoming earnings report date?
PaxMedica, Inc.’s upcoming earnings report date is May 15, 2023 which is 21 days ago.
How were PaxMedica, Inc.’s earnings last quarter?
PaxMedica, Inc. released its earnings results on Mar 29, 2023. The company reported -$0.434 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.434.
Is PaxMedica, Inc. overvalued?
According to Wall Street analysts PaxMedica, Inc.’s price is currently Overvalued.
Does PaxMedica, Inc. pay dividends?
PaxMedica, Inc. does not currently pay dividends.
What is PaxMedica, Inc.’s EPS estimate?
PaxMedica, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PaxMedica, Inc. have?
PaxMedica, Inc. has 14,619,477 shares outstanding.
What happened to PaxMedica, Inc.’s price movement after its last earnings report?
PaxMedica, Inc. reported an EPS of -$0.434 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.471%.
Which hedge fund is a major shareholder of PaxMedica, Inc.?
Currently, no hedge funds are holding shares in PXMD
---
PaxMedica, Inc. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
778.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PaxMedica, Inc.
PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.
---
Top 5 ETFs holding PXMD
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold PXMD. The ETFs are listed according to market value of PXMD within the ETF
---
Satsuma Pharmaceuticals
―
Lowell Farms
―
Zynerba Pharmaceuticals
―
Real Brands
―
Angion Biomedica
―
---